MEDPLUS658.75

Medplus Health Services Ltd.

· Consumer Services
₹ CrorePeersAPOLLOHOSPMANYAVARMSTCLTDNESCOJUSTDIALJSLLQUESSIXIGOMcap ₹7,909 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
MEDPLUS
FY26
APOLLOHOSP
FY26
MANYAVAR
FY25
MSTCLTD
FY26
Peer
Median
Valuation — at last close
P/E35.94×65.86×35.88×23.65×35.88× +0%
P/B4.01×12.82×5.72×9.27× -57%
EV/EBITDA12.69×34.95×21.23×28.09× -55%
Market Cap₹7,909 Cr₹1.28L Cr₹5,167 Cr₹66,532 Cr -88%
Growth
Revenue CAGR 3Y14.78%14.94%10.03%-19.96%10.03% +47%
Revenue CAGR 5Y17.56%19.03%-13.88%2.58% +582%
Net Income CAGR 3Y63.65%33.35%7.25%-3.35%7.25% +778%
Revenue YoY (latest Q)21.84%20.56%22.74%21.72%21.72% +1%
Net Income YoY (latest Q)-21.67%38.41%37.31%37.50%37.50% -158%
Profitability
EBITDA Margin8.81%14.94%46.35%60.63%46.35% -81%
Net Income Margin3.19%7.94%28.02%59.09%28.02% -89%
Return on Common Equity11.12%19.47%21.75%24.16%21.75% -49%
Return on Capital Employed10.01%18.41%20.87%22.87%20.87% -52%
Return on Assets5.58%9.02%14.14%10.86%10.86% -49%
Credit & Quality
Total Debt/Equity0.00×0.57×0.16×0.36× -100%
Interest Coverage2.69×6.44×8.87×7.65× -65%
Scale — latest FY
Revenue / Total Income₹6,892 Cr₹25,229 Cr₹1,386 Cr₹370 Cr₹1,386 Cr +397%
Net Income₹220 Cr₹2,003 Cr₹388 Cr₹218 Cr₹388 Cr -43%
Total Assets₹3,933 Cr₹22,197 Cr₹2,747 Cr₹2,011 Cr₹2,747 Cr +43%
EPS₹18.33₹135.04₹15.99₹31.03₹31.03 -41%
Book Value per Share₹164.48₹693.64₹128.4₹411.02 -60%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.